

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/831,629	08/17/2001	Rina Aharoni	AHARONI 5B	6949
1444 7590 10/22/2004			EXAMINER	
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW			LUKTON, DAVID	
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1653	
			DATE MAN ED 10/23/200	

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)
Office A. (1 0	09/831,629	AHARONI ET AL.
Office Action Summary	Examiner	Art Unit
	David Lukton	1653
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reg. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a reply be tilted. In within the statutory minimum of thirty (30) day I will apply and will expire SIX (6) MONTHS from It cause the application to become ARANDONIA	mely filed ys will be considered timely. If the mailing date of this communication.
Status		
 1) Responsive to communication(s) filed on 09 A 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowed closed in accordance with the practice under A 	s action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 16-30 and 32-34 is/are pending in the 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 16-30 and 32-34 are subject to restrict the specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The eath or deplacement is a biasted to be the first to the section of the	er. cepted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is objected to by the I drawing(s) be held in abeyance.	Examiner. e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Ex	xaminer. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application rity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage
attachment(s)		:
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	

Pursuant to the directives of the response filed 8/9/04, claims 1-15 and 31 have been cancelled, claims 16, 32, 33 amended, and claim 34 added. Claims 16-30 and 32-34 are now pending.

Applicants have continued to traverse the restriction requirement. Applicants' arguments are found non-persuasive. However, if applicants are requesting a change in the restriction from compositions to methods, this request is granted.

The previous species elections remain in force:

(a) the peptide (or mixture of peptides) that is administered is copolymer-1 having all-L amino acids, (b) the peptide (or mixture of peptides) that is administered has an average MW of 7 kD, and (c) the peptide (or mixture of peptides) that is administered has net positive charge.

Given the change in restriction from compositions to methods, two additional species elections are required:

- (d) election of either graft-versus-host disease or host versus graft disease; and
- (e) a specific organ or tissue that is to be transplanted from one mammal to another.

With regard to the first of these (GVDH or HVGD), applicants may choose to argue, in

response to a \$103 rejection, that a given method of treating GVDH does not render obvious a method of treating HVGD. Such an argument may or may not be found persuasive, but such an argument, when given by applicants, will vindicate this election requirement.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber, can be reached at 571-272-0925. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

DAVID LUTTON
PATENT EXAMINER
GROUP 1550